Nations Financial Group Inc. IA ADV Has $2.37 Million Position in Zoetis Inc. (NYSE:ZTS)

Nations Financial Group Inc. IA ADV grew its position in Zoetis Inc. (NYSE:ZTS) by 32.4% in the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 12,143 shares of the company’s stock after purchasing an additional 2,971 shares during the quarter. Nations Financial Group Inc. IA ADV’s holdings in Zoetis were worth $2,373,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. First Personal Financial Services acquired a new position in shares of Zoetis in the 3rd quarter valued at approximately $33,000. Capital Performance Advisors LLP acquired a new position in Zoetis during the 3rd quarter worth approximately $33,000. Quarry LP increased its position in Zoetis by 273.2% during the 2nd quarter. Quarry LP now owns 209 shares of the company’s stock worth $36,000 after purchasing an additional 153 shares in the last quarter. Fortitude Family Office LLC increased its position in Zoetis by 1,387.5% during the 3rd quarter. Fortitude Family Office LLC now owns 238 shares of the company’s stock worth $46,000 after purchasing an additional 222 shares in the last quarter. Finally, LRI Investments LLC acquired a new position in Zoetis during the 1st quarter worth approximately $43,000. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research firms recently issued reports on ZTS. Piper Sandler upped their price objective on shares of Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 14th. BTIG Research upped their price objective on shares of Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a research report on Monday, August 12th. Stifel Nicolaus boosted their target price on shares of Zoetis from $200.00 to $210.00 and gave the stock a “buy” rating in a report on Wednesday, September 18th. Argus raised shares of Zoetis to a “strong-buy” rating in a report on Friday, August 9th. Finally, JPMorgan Chase & Co. boosted their target price on shares of Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a report on Friday, October 11th. Ten research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $221.44.

Zoetis Trading Down 0.4 %

NYSE:ZTS opened at $176.16 on Tuesday. The firm’s fifty day moving average is $188.15 and its 200-day moving average is $179.77. The company has a debt-to-equity ratio of 1.26, a quick ratio of 2.09 and a current ratio of 3.69. Zoetis Inc. has a 52 week low of $144.80 and a 52 week high of $201.92. The firm has a market cap of $79.48 billion, a P/E ratio of 33.11, a P/E/G ratio of 2.71 and a beta of 0.90.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Monday, November 4th. The company reported $1.58 EPS for the quarter, beating analysts’ consensus estimates of $1.46 by $0.12. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. The company had revenue of $2.40 billion for the quarter, compared to analyst estimates of $2.29 billion. During the same period in the prior year, the firm posted $1.36 EPS. The company’s quarterly revenue was up 11.6% on a year-over-year basis. Equities analysts expect that Zoetis Inc. will post 5.9 earnings per share for the current year.

Zoetis Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 3rd. Stockholders of record on Thursday, October 31st will be paid a $0.432 dividend. This represents a $1.73 dividend on an annualized basis and a dividend yield of 0.98%. The ex-dividend date is Thursday, October 31st. Zoetis’s dividend payout ratio is currently 32.33%.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.